Drug Trial Radar · NCT07793929
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
Feb 8, 2028
Study completion Feb 8, 2028
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.
Conditions
- End Stage Renal Disease
- Renal Impairment
- Obesity
- Overweight
Interventions
RibupatideDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35
- Area Under Concentration Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-t) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35
- Area Under Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of RibupatideTime frame: Predose up to 816 hours postdose on Day 35
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kailera Clinical Site
Orlando, Florida · Recruiting
Kailera Clinical Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.